Breaking News

PharmaCell To Purchase TiGenix Production Facility

By Kristin Brooks | January 24, 2014

Expands cell therapy production, establishes long-term manufacturing agreement

PharmaCell B.V. a contract manufacturer for Cellular Therapies and Regenerative Medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its cell therapy production facility in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product, ChondroCelect, for cartilage repair.
PharmaCell will acquire the facility, including its team of employees in production, QC, QA and other functions. ChondroCelect will continue to be manufactured at the site under a long-term agreement with PharmaCell.
In 2012, the Sittard-Geleen manufacturing facility successfully passed cGMP inspection by the Dutch authorities, and obtained approval from the EMA for the production of ChondroCelect. PharmaCell plans to produce other commercial and investigational cell therapy and regenerative medicine products at the site.
Alexander Vos, chief executive officer of PharmaCell B.V., said, “The new partnership with TiGenix is a further step forward to strengthen our business in support of the development of the cell therapy industry in Europe. PharmaCell and TiGenix have created a collaborative business model for cell therapeutics in general and for ChondroCelect in particular.”

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision